ArticleMedicine2019

Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol.

Mitsuru Miyachi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.